Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1 CNS 1

Conditions

Low-grade Glioma 1

Interventions

TIC10 compound 5 trametinib 4 dabrafenib 4 Crizotinib 3 selpercatinib 2 naxitamab 2 entrectinib 2 Trastuzumab 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 AZD 6244 2 vorasidenib 1 ulixertinib 1 tucatinib 1 trastuzumab biosimilar HLX02 1 tovorafenib 1 sodium thiosulfate 1 sapanisertib 1 sacituzumab govitecan 1 relatlimab 1 pertuzumab 1 palbociclib 1 osimertinib 1 omipalisib 1 mirdametinib 1 lutetium Lu 177 dotatate 1 larotrectinib 1 ipatasertib 1 erdafitinib 1 defactinib 1 copper dotatate CU-64 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × tovorafenib × CNS × Clear all

NCT04775485 2025-04-10

FIREFLY-1

Day One Biopharmaceuticals, Inc.

Phase 2 Recruiting

141 enrolled 1 FDA

CNSOther solid neoplasm

Low-grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡